Hereditary Pancreatitis Treatments

Find Hereditary Pancreatitis Treatments

Generic Name

MetFORMIN

Brand Names

Actoplus, Alogliptin, Dapagliflozin, Glipizide, Glumetza, Glyburide, Glyburide-MetFORMIN, Invokamet, Janumet, Jentadueto, Kazano, Linagliptin, Pioglitazole, Pioglitazone, Riomet, Saxagliptin, Segluromet, Sitagliptin, Synjardy, Trijardy, Xigduo, Zituvimet

FDA approval date: January 24, 2002

Classification: Biguanide

Form: Tablet, Solution

What is Actoplus (MetFORMIN)?

ACTOPLUS MET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use ACTOPLUS MET is not recommended to treat type 1 diabetes mellitus or diabetic ketoacidosis. ACTOPLUS MET is a combination of pioglitazone, a thiazolidinedione agonist of peroxisome proliferator receptor gamma, and metformin hydrochloride , a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use : Not recommended for treatment of type 1 diabetes or diabetic ketoacidosis.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

ImproviNg Coronary Vascular Health in Women With Risk Factors fOR Myocardial Infarction Type 2 (INFORM-2)

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Other

Study Phase: Phase 2

Summary: Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a stu...

SGLT2i in Calcium Kidney Stones

Enrollment Status: Recruiting

Publish Date: September 04, 2026

Intervention Type: Drug

Study Phase: Early Phase 1

Summary: This study is looking at whether empagliflozin, a medication typically used for diabetes and heart conditions, may affect factors that contribute to kidney stone formation. The research focuses on people who have had calcium-based kidney stones, i.e. calcium oxalate or calcium phosphate stones. Previous studies in those without kidney stones found that empagliflozin increased urinary citrate level...

A Phase I, Single-Centre, Randomised, Single-dose, Open-label, 2-period, 2-way Crossover Study to Assess the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin in Participants With Kidney Failure

Enrollment Status: Recruiting

Publish Date: September 04, 2026

Intervention Type: Drug

Study Phase: Phase 1

Summary: The purpose of this study is to investigate the effect of HD on single oral dose PK, safety, and tolerability of balcinrenone/dapagliflozin to male and female participants with kidney failure on intermittent HD.

View All Clinical Trials